MLYS — Mineralys Therapeutics, Inc.

Summary of Mineralys Therapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, the company reported cash, cash equivalents, and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024.
• R&D Expenses: Total R&D expenses for 2025 were $132 million, down from $168.6 million in 2024. Q4 R&D expenses were $24.4 million, compared to $44.6 million in Q4 2024, primarily due to the completion of lorundrostat’s pivotal program.
• G&A Expenses: G&A expenses increased to $38.6 million for 2025 from $23.8 million in 2024, with Q4 expenses at $13.9 million versus $7.2 million in Q4 2024, driven by higher compensation and professional fees.
• Net Loss: The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024. Q4 net loss was $32.2 million, down from $48.9 million in Q4 2024.

2. Strategic Updates and Business Highlights

• NDA Acceptance: The FDA accepted the New Drug Application (NDA) for lorundrostat for treating hypertension, with a PDUFA target action date set for December 22, 2026.
• Clinical Trials: Five positive clinical trials have been completed, demonstrating significant blood pressure reduction and a favorable safety profile for lorundrostat.
• Market Access Planning: The company has initiated market access planning and payer engagement to ensure successful product launch and uptake.
• Exploratory Trials: Results from the EXPLORER-OSA trial indicated blood pressure reductions in patients with obstructive sleep apnea, although the primary endpoint (AHI) was not met.

3. Forward Guidance and Outlook

• Funding: The current cash position is expected to support operations and planned clinical trials through 2028.
• Market Strategy: The company is preparing for the launch of lorundrostat, focusing on third-line or later treatment for resistant hypertension, with ongoing discussions with payers to ensure access.
• Future Development: Mineralys is exploring additional indications for lorundrostat, particularly in comorbid conditions related to hypertension.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The potential launch of a competing product from AstraZeneca in the second quarter of 2026 poses a challenge for lorundrostat's market entry.
• Trial Limitations: Concerns were raised about the design and duration of the EXPLORER-OSA trial, which may have limited its ability to demonstrate efficacy on the primary endpoint.
• Market Dynamics: The company is navigating complex payer landscapes and must ensure favorable coverage for lorundrostat amid competitive pricing pressures.

5. Notable Q&A Insights

• Commercial Strategy: The company is assessing the optimal number of sales representatives needed for the launch and is targeting a mix of primary care and specialty physicians.
• Partnership Discussions: Mineralys is actively exploring partnerships that could enhance commercial capabilities and support broader development opportunities for lorundrostat.
• Payer Engagement: Positive feedback from payers regarding lorundrostat's value proposition was noted, with ongoing dialogues to secure access for patients.
• Future Indications: The company is considering various comorbidities related to hypertension for future development, emphasizing the importance of addressing dysregulated aldosterone.

Overall, Mineralys Therapeutics is positioned for a significant product launch with lorundrostat, backed by strong clinical data and a robust financial position, but faces competitive and operational challenges that need to be managed effectively.